Prophylactic-dose direct oral anticoagulants for non-hospitalised people with Covid-19

Background: Several reviews have been conducted on thromboprophylaxis in non-hospitalised patients with coronavirus disease 2019 (COVID-19). In this systematic review and meta-analysis, we sought to investigate the impact of prophylactic-dose direct oral anticoagulants (DOACs) in this population. Methods: We searched PubMed, Web of Science, EMBASE and Cochrane Library for randomised controlled trials (RCTs) comparing prophylactic-dose DOACs with placebo or no treatment in non-hospitalised patients with COVID-19 until September 2023. The primary efficacy outcome was a composite of all-cause mortality and thromboembolic events, while major bleeding events were the primary safety outcome. We expressed continuous outcome data as mean differences (MDs) with 95% confidence intervals (CIs) and dichotomous outcome data as risk ratios (RRs) with 95% CIs. Results: = 0%)). The use of prophylactic-dose DOACs was also associated with a reduction in venous thromboembolism, with no difference in all-cause mortality, arterial thromboembolism, hospitalisations, and clinically relevant nonmajor bleeding between two groups. Sensitivity analyses with the leave-one-out method for the primary efficacy and safety outcome did not change the effect estimate substantially. Conclusions: We found that prophylaxis-dose DOACs could significantly improve clinical outcomes and reduce venous thrombotic events without increasing the risk of major bleeding events compared with placebo or no treatment in non-hospitalised patients with COVID-19. Registration: PROSPERO: CRD42023466889

Cochrane Library · Confidence interval · Meta-analysis · Placebo · Population · Randomized controlled trial · Relative risk · COVID-19 Clinical Research Studies · Heparin-Induced Thrombocytopenia and Thrombosis · Medicine · Venous Thromboembolism Diagnosis and Management · Internal Medicine

• The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

  Open Access•Julian P T Higgins, D G Altman et al.•BMJ•2011

  Incluir item

• Efficacy and Safety of the mRNA-1273 Sars-CoV-2 Vaccine

  Open Access•Lindsey R Baden, Hana M El Sahly et al.•New England Journal of Medicine•2021

  Incluir item